Volume 5.43 | Nov 18

Hematopoiesis News 5.43 November 18, 2014
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  HN on Twitter
 
TOP STORY
Before There Will Be Blood
Researchers describe the surprising and crucial involvement of a pro-inflammatory signaling protein in the creation of hematopoietic stem cells (HSCs) during embryonic development, a finding that could help scientists to finally reproduce HSCs for therapeutic use. [Press release from the University of California, San Diego discussing online prepublication in Cell] Press Release | Abstract | Graphical Abstract
Free Poster: Quick Reference for Mouse Immune Cell Frequencies and Percentages
 
PUBLICATIONS (Ranked by impact factor of the journal)
GPI-80 Defines Self-Renewal Ability in Hematopoietic Stem Cells during Human Development
Scientists discovered that the glycophosphatidylinositol-anchored surface protein GPI-80 defines a subpopulation of human fetal liver hematopoietic stem/progenitor cells with self-renewal ability. [Cell Stem Cell] Abstract | Graphical Abstract | Press Release

Identification of Cdca7 as a Novel Notch Transcriptional Target Involved in Hematopoietic Stem Cell Emergence
Researchers found that during embryonic hematopoietic development, expression of Cdca7 is restricted to the hematopoietic clusters of the aorta, and it is strongly up-regulated in the hemogenic population during human embryonic stem cell hematopoietic differentiation in a Notch-dependent manner. [J Exp Med] Abstract

Inflammatory Signaling Regulates Embryonic Hematopoietic Stem and Progenitor Cell Production
Scientists show that sterile tonic inflammatory signaling regulates embryonic hematopoietic stem and progenitor cells formation. Expression profiling of progenitors with lymphoid potential and hematopoietic stem cells from aorta/gonad/mesonephros regions of midgestation mouse embryos revealed a robust innate immune/inflammatory signature. [Genes Dev] Abstract

Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis
In leukemic cells, investigators show constitutive activation of focal adhesion kinase (FAK) whose inhibition represses leukemogenesis. Downstream of FAK, activation of Rac1 is regulated by RacGEF Tiam1, whose inhibition prolongs the survival of leukemic mice. [Cell Rep] Full Article | Graphical Abstract

Coordinate Expansion of Murine Hematopoietic and Mesenchymal Stem Cell Compartments by SHIPi
Scientists show here that treatment of mice with aminosteroid inhibitors of SHIP1 (SHIPi) more than doubles the size of the adult mesenchymal stem cell compartment while simultaneously expanding the hematopoietic stem cell pool six-fold. [Stem Cells] Abstracts

In Vitro Human Embryonic Stem Cell Hematopoiesis Mimics MYB-Independent Yolk Sac Hematopoiesis
Since Myb was reported to be an excellent marker for hematopoietic stem cell-dependent hematopoiesis, investigators generated a MYB-eGFP reporter human embryonic stem cell line to study formation of hematopoietic progenitor cells in vitro. [Haematologica] Abstract | Full Article

Hematopoietic Stem/Progenitor Cell Sources to Generate Reticulocytes for Plasmodium vivax Culture
Investigators compared the production of reticulocytes using an established in vitro culture system from three different sources of hematopoietic stem/progenitor cells, i.e. umbilical cord blood, bone marrow and adult peripheral blood. [PLoS One] Full Article

Co-Transplantation of Hematopoietic Stem Cells and Cxcr4 Gene-Transduced Mesenchymal Stem Cells Promotes Hematopoiesis
The effects of co-transplantation of hematopoietic stem cells and mouse bone marrow-derived mesenchymal stem cells overexpressing CXCR4 (CXCR4-MSC) on CXCR4-MSC homing capacity and the reconstitution potential in lethally irradiated mice were evaluated. [Cell Biochem Biophys] Abstract

An Expandable, Inducible Hemangioblast State Regulated by Fibroblast Growth Factor
Investigators identified six transcription factors, Gata2, Lmo2, Mycn, Pitx2, Sox17, and Tal1, that “trap” murine cells in a proliferative state and endow them with a hemangioblast potential. [Stem Cell Rep]
Full Article | Press Release

CLINICAL RESEARCH

Incidence, Risk Factors, and Clinical Outcome of Leukemia Relapses with Loss of the Mismatched HLA after Partially-Incompatible Hematopoietic Stem Cell Transplantation
Genomic loss of the mismatched HLA is a recently described mechanism of leukemia immune escape and relapse after allogeneic hematopoietic stem cell transplantation. Investigators first evaluated its incidence, risk factors, and outcome in 233 consecutive transplants from partially HLA-mismatched related and unrelated donors. [Leukemia] Abstract

Hematopoietic Stem Cell Transplantation for X-Linked Thrombocytopenia with Mutations in the WAS Gene
To answer the question whether hematopoietic stem cell transplantation (HSCT) offers a viable therapeutic option in X-linked thrombocytopenia (XLT), researchers retrospectively investigated the outcome of HSCT in a cohort of 24 XLT patients who received HSCT at 14 transplant centers in the United States, Italy, Germany, Canada, and Japan. [J Clin Immunol] Abstract

[Free On-Demand Webinar] Potential Applications of ALDH+ Cells in Regenerative Medicine - Watch Now.
 
REVIEWS
Chronic Granulomatous Disease – Conventional Treatment vs. Hematopoietic Stem Cell Transplantation: An Update
The authors update and summarize the recent findings in conventional treatment and hematopoietic stem cell transplantation in chronic granulomatous disease (CGD). They also summarize the contemporary view on when hematopoietic stem cell transplantation should be the preferred treatment of choice in CGD. [Curr Opin Hematol] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

Don't miss ASGCT 18th Annual Meeting!
 
INDUSTRY NEWS
AstraZeneca, Pharmacyclics and Janssen Partner on Immuno-Oncology Combination Trials with IMBRUVICA® for Hematological Cancer
AstraZeneca, Pharmacyclics, Inc. and Janssen Research & Development, LLC announced that they have entered into a clinical trial collaboration to evaluate the efficacy and safety of AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with IMBRUVICA® (ibrutinib), an oral Bruton’s tyrosine kinase inhibitor, co-developed by Pharmacyclics and Janssen and commercialized outside the US by Janssen affiliates. [AstraZeneca] Press Release

GlycoMimetics Announces Positive Top-Line Results from Phase I Study of GMI-1271 in Healthy Volunteers
GlycoMimetics, Inc. announced that healthy volunteers in a Phase I clinical study of GMI-1271 tolerated the drug candidate well, and that the pharmacokinetics for the drug candidate were as predicted based on preclinical data. Based on these data, GlycoMimetics is planning a Phase I/II trial of GMI-1271 as an adjunct to standard chemotherapy in patients with acute myeloid leukemia. [GlycoMimetics, Inc.] Press Release

Cord Blood Registry Sponsors 2014 World Stem Cell Summit
Cord Blood Registry® announced that the company is a platinum sponsor of the 10th Annual World Stem Cell Summit, the largest global meeting of stem cell science and regenerative medicine stakeholders. [Cord Blood Registry®] Press Release

From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW American Society of Gene & Cell Therapy (ASGCT) 18th Annual Meeting
May 13-16, 2015
New Orleans, United States

Visit our events page to see a complete list of events in the hematopoiesis community.
 
JOB OPPORTUNITIES
NEW Head of Cellular and Molecular Therapies Laboratory (NHS Blood & Transplant)

NEW Postdoctoral Researcher – Chromatin and Epigenetic Regulation (Van Andel Research Institute)

Postdoctoral Position – Post-Transcriptional Control of Gene Expression in Hematopoietic Stem Cells (Lund University)

Postdoctoral Fellow – Stem Cell Biology Gene Expression and Regulation (The University of Texas Medical School At Houston)

PhD Studentship – Discovery of Key Regulators of Normal and Leukemic Stem Cell Functions (University of Edinburgh)

Postdoctoral Position – NK Cell and Leukemia Research (Children’s Hospital Los Angeles)

Postdoctoral Research Associate – Mechanisms Underlying Hematopoiesis and Leukemogenesis (University of Wisconsin School of Medicine and Public Health)

Postdoctoral Position – Molecular Properties of Leukemic Stem Cells (BC Cancer Agency)

Stem Cell Biology Program Director (Blood Research Institute of BloodCenter of Wisconsin)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us